BRIEF-Avadel Pharmaceuticals Receives Orphan Drug Designation From FDA For Lumryz

Reuters
05 Jun
BRIEF-Avadel Pharmaceuticals Receives Orphan Drug Designation From FDA For Lumryz

June 5 (Reuters) - Avadel Pharmaceuticals PLC AVDL.O:

  • AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR LUMRYZ™ (SODIUM OXYBATE) FOR EXTENDED-RELEASE ORAL SUSPENSION FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA

Source text: ID:nGNX8lGQVk

Further company coverage: AVDL.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10